Empresa Colombiana de Productos Veterinarios
Colombian veterinary and agricultural company that manufactures and distributes vaccines, biologics, veterinary pharmaceuticals, nutritional supplements and crop‑protection products. Operates manufacturing and laboratory facilities undergoing GMP/modernization activities, provides cold‑chain distribution, field epidemiology and diagnostic sampling, pharmacovigilance and technical training for vaccination campaigns, and conducts R&D including vaccine development for aquaculture and formulation of companion‑animal supplements and cosmetic products.
Industries
Nr. of Employees
large (251-1000)
Empresa Colombiana de Productos Veterinarios
Av. Eldorado 82-93, Bogotá, Colombia; Código Postal: 110931
Products
Veterinary vaccines (campaign‑scale)
Vaccines for livestock disease control used in mass vaccination campaigns.
Veterinary pharmaceuticals and supplements
Formulated antibiotics, antiparasitics, hormones, vitamins and nutritional supplements for production and companion animals.
Companion‑animal nutritional supplements (molecular activation)
Nutritional supplements for companion and aquatic animals formulated using molecular activation technology.
Companion‑animal cosmetic and grooming products
Topical cosmetic and grooming products for pets, including shampoos, ear and eye care solutions and related items.
Crop‑protection products and fertilizers
Herbicides, insecticides, fungicides and fertilizers for agricultural use.
Veterinary vaccines (campaign‑scale)
Vaccines for livestock disease control used in mass vaccination campaigns.
Veterinary pharmaceuticals and supplements
Formulated antibiotics, antiparasitics, hormones, vitamins and nutritional supplements for production and companion animals.
Companion‑animal nutritional supplements (molecular activation)
Nutritional supplements for companion and aquatic animals formulated using molecular activation technology.
Companion‑animal cosmetic and grooming products
Topical cosmetic and grooming products for pets, including shampoos, ear and eye care solutions and related items.
Crop‑protection products and fertilizers
Herbicides, insecticides, fungicides and fertilizers for agricultural use.
Services
Production and release support for vaccines used in national vaccination campaigns.
Development of tailored immunogens including autogenous vaccine projects for aquaculture pathogens.
Training programs for vaccinators and field technicians on handling biologicals and managing adverse reactions during campaigns.
Project management and tender administration for design and modernization of biologics production facilities.
Formulation, manufacture and commercial distribution of nutritional supplements (including molecular activation methods) and cosmetic/grooming products for companion animals.
Production and release support for vaccines used in national vaccination campaigns.
Development of tailored immunogens including autogenous vaccine projects for aquaculture pathogens.
Training programs for vaccinators and field technicians on handling biologicals and managing adverse reactions during campaigns.
Project management and tender administration for design and modernization of biologics production facilities.
Formulation, manufacture and commercial distribution of nutritional supplements (including molecular activation methods) and cosmetic/grooming products for companion animals.
Expertise Areas
- Veterinary vaccine manufacturing
- GMP facility modernization and regulatory alignment
- Pharmacovigilance and field adverse‑event response
- Field epidemiology and diagnostic sampling
Key Technologies
- Vaccine formulation and lyophilization
- Fermentation and inactivation processes
- Cold‑chain and refrigerated distribution
- Field diagnostic sampling and necropsy procedures
News & Updates
Public event to share company results.
Announcement of R&D progress on an autogenous bivalent vaccine for Streptococcus infections in tilapia.
Reference to distribution activity of tens of millions of vaccine doses to address Streptococcus agalactiae impacts in tilapia production.
Reported production of 32,865,445 doses of one campaign vaccine and 1,452,515 doses of another vaccine for the 2020 cycle.
Reported distribution contribution cited as 89 million doses for an aquaculture emergency response.
Public event to share company results.
Announcement of R&D progress on an autogenous bivalent vaccine for Streptococcus infections in tilapia.
Reference to distribution activity of tens of millions of vaccine doses to address Streptococcus agalactiae impacts in tilapia production.
Reported production of 32,865,445 doses of one campaign vaccine and 1,452,515 doses of another vaccine for the 2020 cycle.
Reported distribution contribution cited as 89 million doses for an aquaculture emergency response.